ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,377,161, issued on Aug. 5, was assigned to PHILOGEN S.P.A. (Siena, Italy).
"TNF-alpha immunoconjugate therapy for the treatment of brain tumors" was invented by Theresa Hemmerle (Otelfingen, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to immunoconjugates, compositions, methods and uses for treating brain tumors, especially glioma, by administration of a tumour necrosis factor alpha (TNFAlpha) immunoconjugate."
The patent was filed on Oct. 3, 2023, under Application No. 18/480,153.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2...